Pharmaceutical companies are increasingly shifting their focus toward innovative therapies, yet mature medicines continue to play a crucial role in healthcare systems, particularly in the Japan-Asia-Pacific (JAPAC) region. Despite the industry’s emphasis on new drug modalities, these established treatments remain integral in managing infectious diseases, cardiovascular health, oncology, and chronic conditions, impacting millions of patients annually.
Healthcare professionals have built extensive experience with mature medicines, establishing their efficacy and safety profiles over years of use. However, the post-patent landscape for these medications can vary significantly. High-volume primary care products often attract numerous generic competitors, offering a wide range of treatment options. Conversely, specialist medicines catering to smaller patient populations frequently face a lack of generic alternatives, resulting in a limited number of suppliers. This can complicate access to these essential medicines, particularly in regions with diverse healthcare systems like JAPAC, where the dynamics of reimbursement and availability differ significantly.
The stability provided by mature medicines is vital for healthcare system resilience. While innovation is essential for future treatment advances, reliable access to well-established therapies helps maintain continuity of care, ensuring patients receive consistent treatment and preserving trust in established protocols. Recent experiences have underscored the importance of maintaining the regulatory, manufacturing, and distribution frameworks that support these medicines, especially during times of supply disruptions.
Maintaining the commercial viability of medications after patent expiration presents substantial challenges. Even when patient demand persists, products may experience increasing pricing pressure and competition. Pharmaceutical companies must juggle the support for these established treatments while advancing new therapies, requiring complex portfolio management strategies—especially across the JAPAC region, known for its varied regulatory and market environments.
To mitigate these complexities, many pharmaceutical firms are exploring partnerships with specialized organizations. These collaborations can enhance the delivery and management of mature medicines, ensuring they remain accessible to patients while allowing innovator companies to concentrate resources on their core capabilities.
For biopharmaceutical companies navigating these issues, investing in local regulatory expertise and market access is becoming increasingly important. The fragmented landscape of healthcare regulations in the JAPAC region necessitates a flexible approach, with some companies opting to partner with established organizations to streamline operations and ensure market access.
The partnership between Clinigen and ShanZeBIO for the distribution of Avelox across 16 international markets exemplifies the complexities involved in managing established medicines. This collaboration illustrates that effective management extends far beyond production and supply; it requires adept navigation of local regulatory landscapes and dynamic healthcare channels.
As the pharmaceutical industry progresses toward 2027 and beyond, a reevaluation of the commercial lifecycle for medicines is anticipated. Companies are beginning to appreciate that the expiration of patent protections doesn’t signify the end of a product’s lifecycle but rather a transition to a new phase where mature medicines can be repositioned and supported by specialized entities. This shift emphasizes the need for flexibility in partnership models, regulatory frameworks, and supply chains—critical for ensuring sustained access to established medicines across diverse markets.
